<DOC>
	<DOCNO>NCT01579006</DOCNO>
	<brief_summary>This multi-center , observational study evaluate clinical practice pattern , efficacy safety RoActemra/Actemra patient rheumatoid arthritis inadequate response ( intolerant ) treatment non-biological DMARDs one biological agent . Data collect eligible patient initiate RoActemra/Actemra treatment treat physician accord approve label 6 month start treatment .</brief_summary>
	<brief_title>Observational Study RoActemra/Actemra ( Tocilizumab ) Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis Inadequate response ( intolerant ) nonbiological DMARDs one biologic agent Patients initiate treatment RoActemra/Actemra physician 's decision ( accordance local label ) , include patient start treatment RoActemra/Actemra 8 week prior enrolment visit RoActemra/Actemra treatment 8 week prior enrolment visit Previous RoActemra/Actemra treatment clinical trial compassionate use Enrolled ongoing clinical trial and/or treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment RoActemra/Actemra History autoimmune disease joint inflammatory disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>